Plazomicin: A New Aminoglycoside
- 20 July 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 70 (4), 704-709
- https://doi.org/10.1093/cid/ciz640
Abstract
Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae. It has recently been approved by the Food and Drug Administration for the management of complicated urinary tract infections and pyelonephritis caused by susceptible organisms. When compared with meropenem, plazomicin was not inferior. The adverse-event profile for plazomicin was comparable to meropenem except for an increased additional rise in serum creatinine in the plazomicin arm compared with the meropenem arm. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.Keywords
This publication has 36 references indexed in Scilit:
- In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012Antimicrobial Agents and Chemotherapy, 2014
- Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)Journal of Antimicrobial Chemotherapy, 2014
- Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2011
- Aminoglycoside modifying enzymesDrug Resistance Updates, 2010
- Aminoglycoside drugs in clinical practice: an evidence-based approachJournal of Antimicrobial Chemotherapy, 2008
- Do we still need the aminoglycosides?International Journal of Antimicrobial Agents, 2008
- Back to the Future: Using Aminoglycosides Again and How to Dose Them OptimallyClinical Infectious Diseases, 2007
- 16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against AminoglycosidesClinical Infectious Diseases, 2007
- The AminoglycosidesMayo Clinic Proceedings, 1999
- Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparinAntimicrobial Agents and Chemotherapy, 1991